Natural killer cell‐related anti‐tumour adoptive cell immunotherapy

Abstract

AbstractChimeric antigen receptor‐ (CAR‐)modified T cells have been successfully used to treat blood cancer. With the improved research on anti‐tumour adoptive cell therapy, researchers have focused on immune cells other than T lymphocytes. Natural killer (NK) cells have received widespread attention as barriers to natural immunity. Compared to T lymphocyte‐related adoptive cell therapy, the use of NK cells to treat tumours does not cause graft‐versus‐host disease, significantly improving immunity. Moreover, NK cells have more sources than T cells, and the related modified cells are less expensive. NK cells function through several pathways in anti‐tumour mechanisms. Currently, many anti‐tumour clinical trials have used NK cell‐related adoptive cell therapies. In this review, we have summarized the recent progress in NK cell‐related adoptive cellular immunotherapy for tumour treatment and propose the current challenges faced by CAR‐NK cell therapy.